Chimeric Therapeutics Ltd (ASX:CHM) has been issued a patent from the Unites States Patent and Trademark Office covering certain applications of chimeric.
Chimeric has obtained the exclusive option to license the CORE-NK platform, a Clinically validated, Off the shelf, Robust, Enhanced Natural Killer cell.